AbbVie a long, Vyalev becomes one of best selling drugs once controversy fades
Sarepta to be bought, adding to position on a refresh of the model
NVIDIA losing the value crown to memory and now a bear is forming, HBM is a rising cost to them
Spruce Biosciences held long, building up a position in the name
BioCryst held long as a core biotech position in the portfolio
Biohaven nearing FDA approval; back up the truck name already running
Bloom Energy down 12%, could be a short
Optics and transceiver companies crushing it on AI buildout
Prax worth a small buy
Backblaze bought on customer recommendation
Long Insmed
Revolution Medicines a name we like